Trial · NCT05680233
Safety Study of OA-235i in Subjects With Nonalcoholic Steatohepatitis
NCT05680233, Phase 1, Completed, Oasis Pharmaceuticals, LLC
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Safety Study of OA-235i in Subjects With Nonalcoholic Steatohepatitis. Trials, record NCT05680233. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05680233
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Safety Study of OA-235i in Subjects With Nonalcoholic Steatohepatitis
- NCT number
- NCT05680233
- Status
- Completed
- Phases
- Phase 1
- Enrollment
- 24 participants, actual
- Lead sponsor
- Oasis Pharmaceuticals, LLC
- Conditions
- Nonalcoholic Steatohepatitis, Nonalcoholic Fatty Liver
- Interventions
- OA-235i (4 mg), OA-235i (8 mg), OA-235i (16 mg), OA-235i (30 mg), OA-235i (40 mg), OA-235i or placebo
- First posted
- 2023-01-11
- Last updated
- 2025-06-25
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Frequency and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) | 30 Days | Number of participants with treatment-emergent with adverse events (incidence and severity) |
| Secondary | To characterize the OA-235i Pharmacokinetics (PK) by Cmax | 8 Days | OA-235i PK by peak plasma concentration (Cmax) |
| Secondary | To characterize the OA-235i Pharmacokinetics (PK) by t1/2 | 8 Days | OA-235i PK by the terminal elimination half-life (t1/2) |
| Secondary | To characterize the OA-235i Pharmacokinetics (PK) by Tmax | 8 Days | OA-235i PK by time to peak plasma concentration (Tmax) |
| Secondary | To characterize the OA-235i Pharmacokinetics (PK) by AUC | 8 Days | OA-235i PK by area under the plasma concentration versus time curve (AUC) |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| R44DK101240 | Development of PAR2 Pepducins as a Novel NASH Treatment | KULIOPULOS, ATHAN | OASIS PHARMACEUTICALS | NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES | 2017 to 2019 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05680233
GET https://conductscience.org/api/trials/v1/NCT05680233/registered